APONTIS PHARMA AG

  • WKN: A3CMGM
  • ISIN: DE000A3CMGM5
  • Land: Deutschland

Nachricht vom 28.05.2021 | 20:05

APONTIS PHARMA AG: Notification on the implementation of stabilization measures

DGAP-News: APONTIS PHARMA AG / Key word(s): Miscellaneous
28.05.2021 / 20:05
The issuer is solely responsible for the content of this announcement.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

28 May 2021

APONTIS PHARMA AG

Disclosure in accordance with Article 5 para. 4 lit. (b) and para. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("Market Abuse Regulation") of 16 April 2014 and in accordance with Article 6 para. 2 of the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 on the implementation of stabilisation measures

Following the pre-stabilisation announcement dated 29 April 2021, the stabilisation manager mentioned below has informed APONTIS PHARMA AG, Monheim am Rhein, Germany, (contact person: Sven Pauly; Telefon: +49 2173 89 55 4900) that stabilisations (within the meaning of Article 3 para. 2 lit. (d) of the Market Abuse Regulation) have taken place with respect to the offer of the following securities as indicated below:

The Securities:

Issuer: APONTIS PHARMA AG
Guarantor
(if applicable):
n/a
Aggregate nominal amount of the offer
(excluding over-allotment option):
4,600,000
Description: Ordinary shares with no par value
ISIN DE000A3CMGM5
Offer price: EUR 19.00
 

Stabilisation:

Stabilisation manager: Hauck & Aufhäuser Privatbankiers
Aktiengesellschaft
Existence, maximum size of
the over-allotment option:
690,000 ordinary shares with no par value
Stabilisation marketplace: Frankfurt Stock Exchange, Xetra (XETR)
 

Stabilisations:

Trade date and time Purchase (P)/ Sale (S) Nominal value
(pieces)
Execution
price (0.0000)
Currency code
(ISO 4217)
Market place MIC
(ISO 10386)
20.05.2021
17:36:02
P 3,000 18.2500 EUR XETR
20.05.2021
17:36:02
P 3,000 18.2500 EUR XETR
20.05.2021
17:36:02
P 2,000 18.2500 EUR XETR
28.05.2021
10:49:56
P 1,180 17.9500 EUR XETR
28.05.2021
10:49:56
P 20 18.0000 EUR XETR
28.05.2021
10:50:33
P 132 17.9000 EUR XETR
28.05.2021
10:50:33
P 488 17.9500 EUR XETR
28.05.2021
10:50:33
P 30 18.0000 EUR XETR
28.05.2021
10:50:49
P 600 18.0000 EUR XETR
 
Sum Aggregated
volume
(pieces)
Weighted price Currency code
(ISO 4217I
  10,450 18.1821 EUR
 

IMPORTANT NOTICE

These materials may not be, directly or indirectly, published, distributed or transmitted in or into the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of Apontis Pharma AG (the "Company") in the United States, Australia, Canada, Japan or any other jurisdiction in which such offer or solicitation is unlawful. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). There will be no public offering of the securities in the United States. The Securities of the Company have not been, and will not be, registered under the Securities Act. The securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan subject to certain exceptions.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.), or (iii) to whom an invitation or inducement to engage in an investment activity (within the meaning of section 21 of the United Kingdom Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. The securities have already been sold.



28.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Vectron Systems AG legt verstärkt Fokus auf Digitalgeschäft

Nachdem die Vectron Systems AG bislang insbesondere Kassensysteme verkauft hat, wird nun das Digitalgeschäft stärker in den Fokus rücken. Damit sollen die wiederkehrenden Einnahmen und die Wertschöpfung je Kunde deutlich erhöht werden. Über Cloud-Module können die Kunden nun mehrere digitale Services, die sie sonst über viele Einzelverträge abdecken, direkt mit dem Erwerb der Vectron-Kassen über den Fachhandel dazubuchen. Wir haben die Vectron Systems AG im Rahmen eines DCF-Modells bewertet und ein Kursziel in Höhe von 21,15 € ermittelt und vergeben das Rating KAUFEN.

Aktueller Webcast

fashionette AG

Earnings Call Q1 2021

17. Juni 2021

Aktuelle Research-Studie

q.beyond AG

Original-Research: q.beyond AG (von Montega AG): Kaufen

17. Juni 2021